SCHEMBL4712658

SCHEMBL4712658

Cc1cccc(C=Cc2cccc(C)n2)n1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.76
GRM4 Q14833 3/20 0.76
ALDH1A1 P00352 2/20 0.76
NPC1 O15118 2/20 0.76
MEN1 O00255 2/20 0.76
KMT2A Q03164 2/20 0.76
GRM5 P41594 1/20 0.76
SMN1; SMN2 Q16637 1/20 0.76
NPSR1 Q6W5P4 1/20 0.76
HDAC6 Q9UBN7 1/20 0.76
KDM4E B2RXH2 1/20 0.76
CYP3A4 P08684 1/20 0.76
CYP2D6 P10635 1/20 0.76
CYP2C9 P11712 1/20 0.76
PKM P14618 1/20 0.76
HPGD P15428 1/20 0.76
TSHR P16473 1/20 0.76
NFKB1 P19838 1/20 0.76
CYP2C19 P33261 1/20 0.76
THPO P40225 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9000525 0.91 ALDH1A1 (0.66) RAB9AGRM4ALDH1A1NPC1MEN1
SCHEMBL13820472 0.88 RAB9A (0.62) RAB9AGRM4ALDH1A1NPC1MEN1
SCHEMBL4711051 0.87 RAB9A (0.67) RAB9AGRM4ALDH1A1NPC1MEN1
SCHEMBL350949 0.87 GRM4 (1.00) RAB9AGRM4ALDH1A1NPC1MEN1
SCHEMBL4711050 0.87 RAB9A (0.67) RAB9AGRM4ALDH1A1NPC1MEN1
SCHEMBL29510104 0.87 GRM4 (1.00) RAB9AGRM4ALDH1A1NPC1MEN1
SCHEMBL179801 0.87 GRM4 (1.00) RAB9AGRM4ALDH1A1NPC1MEN1
SCHEMBL21241331 0.86 ALDH1A1 (0.60) RAB9AGRM4ALDH1A1NPC1MEN1
SCHEMBL5756445 0.86 RAB9A (0.60) RAB9AGRM4ALDH1A1NPC1MEN1
SCHEMBL4711246 0.85 KDM4E (0.76) RAB9AGRM4ALDH1A1NPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP disclosed
US-6656957-B1 Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. NOVARTIS AG (CH) 2003-12-02 US disclosed